Cargando…
Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells
BACKGROUND: The skeleton is the first and most common distant metastatic site for breast cancer. Such metastases complicate cancer management, inducing considerable morbidities and decreasing patient survival. Osteomimetism is part of the complex process of osteotropism of breast cancer cells. Recen...
Autores principales: | Absil, L., Journé, F., Larsimont, D., Body, J. J., Tafforeau, L., Nonclercq, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350202/ https://www.ncbi.nlm.nih.gov/pubmed/32650752 http://dx.doi.org/10.1186/s12885-020-07106-7 |
Ejemplares similares
-
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017) -
The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016) -
The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022) -
Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021) -
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)